title: The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma.
abstract: The tumor necrosis factor (TNF) receptor family includes several important markers of activation in T cells. We examined expression patterns of two T-cell-associated members of these receptors, namely CD30 and OX40/CD134, in 148 cases of T-cell lymphoma to identify possible objective immunohistochemical criteria for subclassification of these tumors. CD30 expression was characteristic of tumors with an anaplastic (46/47 cases [98%]) or large-cell (10/21 [48%]) morphology and was seen in only scattered cells in other tumor types. In contrast, large numbers of OX40/CD134(+) tumors cells were typical of angioimmunoblastic lymphoma (15/16 [94%]), angiocentric lymphoma (4/4), a subset of large-cell lymphomas (10/21 [48%]), and lymphomas with a prominent histiocytic component (6/7 [86%]). Strong OX40/CD134 and CD30 coexpression was seen in only 4% of tumors, typically those with an anaplastic/Hodgkin's-like appearance. OX40/CD134 expression was characteristic of tumors composed of activated CD4(+) T cells and was not seen in small-cell T-cell lymphomas, lymphoblastic lymphomas, or other tumor types, including B-cell lymphomas or carcinomas. These results suggest that immunostaining for OX40/CD134 may be helpful in subclassification of peripheral T-cell lymphomas and that the patterns of TNF receptor family expression in these tumors may parallel those seen within nonneoplastic helper T-cell subsets.
authors.affiliation: Department of Pathology and the Division of Hematopathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
authors.forename: D
authors.initials: D
authors.lastname: Jones
authors.forename: C D
authors.initials: CD
authors.lastname: Fletcher
authors.forename: K
authors.initials: K
authors.lastname: Pulford
authors.forename: A
authors.initials: A
authors.lastname: Shahsafaei
authors.forename: D M
authors.initials: DM
authors.lastname: Dorfman
mesh_terms: D015703:Antigens, CD / Q000032:analysis*; D015415:Biomarkers; D006689:Hodgkin Disease / Q000276:immunology / Q000473:pathology; D006801:Humans; D017730:Ki-1 Antigen / Q000032:analysis*; D008213:Lymphocyte Activation; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000145:classification / Q000276:immunology* / Q000473:pathology; D011971:Receptors, Immunologic / Q000032:analysis; D053262:Receptors, OX40; D018124:Receptors, Tumor Necrosis Factor; D012189:Retrospective Studies; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000032:analysis*
chemical_list: D015703:Antigens, CD; D015415:Biomarkers; D017730:Ki-1 Antigen; D011971:Receptors, Immunologic; D053262:Receptors, OX40; D018124:Receptors, Tumor Necrosis Factor; C505716:TNFRSF4 protein, human; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7